Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cell lines.

Transforming growth factor β (TGF-β) is overexpressed in a wide variety of cancer types including lung adenocarcinoma (LAC), and the TGF-β signaling pathway plays an important role in tumor development. To determine whether blockade of the TGF-β signaling pathway can inhibit the malignant biological behavior of LAC, RNA interference (RNAi) technology was used to silence the expression of TGF-β receptor, type II (TGFβRII) in the LAC cell line, A549, and its effects on cell proliferation, invasion and metastasis were examined. Three specific small interfering RNAs (siRNAs) designed for targeting human TGFβRII were transfected into A549 cells. The expression of TGFβRII was detected by Western blot analysis. Cell proliferation was measured by MTT and clonogenic assays. Cell apoptosis was assessed by flow cytometry. The invasion and metastasis of A549 cells were investigated using the wound healing and Matrigel invasion assays. The expression of PI3K, phosphorylated Smad2, Smad4, Akt, Erk1/2, P38 and MMPs was detected by Western blot analysis. The TGFβRII siRNA significantly reduced the expression of TGFβRII in A549 cells. The knockdown of TGFβRII in A549 cells resulted in the suppression of cell proliferation, invasion and metastasis and induced cell apoptosis. In addition to the Smad-dependent pathway, independent pathways including the Erk MAPK, PI3K/Akt and p38 MAPK pathways, as well as the expression of MMPs and VEGF, were inhibited. In conclusion, TGF-β signaling is required for LAC progression. Therefore, the blockade of this signaling pathway by the down-regulation of TGFβRII using SiRNA may provide a potential gene therapy for LAC.

[1]  N. Kruger,et al.  The bradford method for protein quantitation. , 1988, Methods in molecular biology.

[2]  R. Muschel,et al.  Metalloproteinases in tumor progression: the contribution of MMP-9. , 1994, Invasion & metastasis.

[3]  M. Frazier-Jessen,et al.  TGF-beta: a balancing act. , 1998, International reviews of immunology.

[4]  H. Beug,et al.  TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.

[5]  H. Kato,et al.  Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer , 2001, British Journal of Cancer.

[6]  T. Tsushima,et al.  Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. , 2001, Cancer.

[7]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[8]  M. Korc,et al.  Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  S. Fesik,et al.  Specificity of short interfering RNA determined through gene expression signatures , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Kato,et al.  Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. , 2003, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[11]  P. Friedl,et al.  Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.

[12]  J. Coebergh,et al.  The changing epidemiology of lung cancer in Europe. , 2003, Lung cancer.

[13]  L. Wakefield,et al.  The two faces of transforming growth factor beta in carcinogenesis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[15]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[16]  M. Woodle,et al.  In Vivo Application of RNA Interference: From Functional Genomics to Therapeutics , 2005, Advances in Genetics.

[17]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[19]  F. Bray,et al.  International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising , 2005, International journal of cancer.

[20]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[21]  E. Fuchs,et al.  Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. , 2007, Cancer cell.

[22]  Y. Wan,et al.  Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy , 2007, Clinical Cancer Research.

[23]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[24]  A. Wesołowska,et al.  Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. , 2008, Oncogene.

[25]  M. Duffy,et al.  Cancer invasion and metastasis: changing views , 2008, The Journal of pathology.

[26]  Valérie Ferreira,et al.  VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. , 2008, European journal of cancer.

[27]  M. Moses,et al.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Reiss,et al.  Targeting the Transforming Growth Factor-β pathway inhibits human basal-like breast cancer metastasis , 2010, Molecular Cancer.

[29]  A. Borczuk,et al.  Tgf-beta signaling pathway in lung adenocarcinoma invasion. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  David A Lynch,et al.  Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. , 2010, Journal of the National Cancer Institute.

[31]  H. Uramoto,et al.  Time Trends of Surgical Outcome in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  S. Sheng,et al.  The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. , 2010, Current pharmaceutical design.

[33]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.